131 related articles for article (PubMed ID: 26091641)
21. Perception of validity of clinical and preclinical methods for assessment of torsades de pointes liability.
Pugsley MK; Hancox JC; Curtis MJ
Pharmacol Ther; 2008 Aug; 119(2):115-7. PubMed ID: 18590766
[TBL] [Abstract][Full Text] [Related]
22. Recalibration of nonclinical safety pharmacology assessment to anticipate evolving regulatory expectations.
Pugsley MK; Authier S; Hayes ES; Hamlin RL; Accardi MV; Curtis MJ
J Pharmacol Toxicol Methods; 2016; 81():1-8. PubMed ID: 27343819
[TBL] [Abstract][Full Text] [Related]
23. Drug-induced QT interval prolongation--regulatory guidance and perspectives on hERG channel studies.
Shah RR
Novartis Found Symp; 2005; 266():251-80; discussion 280-5. PubMed ID: 16050273
[TBL] [Abstract][Full Text] [Related]
24. Preclinical cardiac safety assessment of pharmaceutical compounds using an integrated systems-based computer model of the heart.
Bottino D; Penland RC; stamps A; Traebert M; Dumotier B; Georgiva A; Helmlinger G; Lett GS
Prog Biophys Mol Biol; 2006; 90(1-3):414-43. PubMed ID: 16321428
[TBL] [Abstract][Full Text] [Related]
25. hERG-related drug toxicity and models for predicting hERG liability and QT prolongation.
Raschi E; Ceccarini L; De Ponti F; Recanatini M
Expert Opin Drug Metab Toxicol; 2009 Sep; 5(9):1005-21. PubMed ID: 19572824
[TBL] [Abstract][Full Text] [Related]
26. Transmural dispersion of repolarization as a preclinical marker of drug-induced proarrhythmia.
Said TH; Wilson LD; Jeyaraj D; Fossa AA; Rosenbaum DS
J Cardiovasc Pharmacol; 2012 Aug; 60(2):165-71. PubMed ID: 22561361
[TBL] [Abstract][Full Text] [Related]
27. Early drug development: assessment of proarrhythmic risk and cardiovascular safety.
Lester RM; Olbertz J
Expert Rev Clin Pharmacol; 2016 Dec; 9(12):1611-1618. PubMed ID: 27718759
[TBL] [Abstract][Full Text] [Related]
28. Cardiac safety assays.
Heijman J; Voigt N; Carlsson LG; Dobrev D
Curr Opin Pharmacol; 2014 Apr; 15():16-21. PubMed ID: 24721649
[TBL] [Abstract][Full Text] [Related]
29. Preclinical Torsades-de-Pointes screens: advantages and limitations of surrogate and direct approaches in evaluating proarrhythmic risk.
Gintant GA
Pharmacol Ther; 2008 Aug; 119(2):199-209. PubMed ID: 18621077
[TBL] [Abstract][Full Text] [Related]
30. Comparison of sensitivity of surrogate markers of drug-induced torsades de pointes in canine hearts.
Chiba K; Sugiyama A; Takasuna K; Hashimoto K
Eur J Pharmacol; 2004 Oct; 502(1-2):117-22. PubMed ID: 15464097
[TBL] [Abstract][Full Text] [Related]
31. Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation.
Guo L; Guthrie H
J Pharmacol Toxicol Methods; 2005; 52(1):123-35. PubMed ID: 15936217
[TBL] [Abstract][Full Text] [Related]
32. The comparative sensitivity of three in vitro safety pharmacology models for the detection of lidocaine-induced cardiac effects.
Goineau S; Castagné V; Guillaume P; Froget G
J Pharmacol Toxicol Methods; 2012 Jul; 66(1):52-8. PubMed ID: 22691624
[TBL] [Abstract][Full Text] [Related]
33. QT PRODACT: a multi-site study of in vitro action potential assays on 21 compounds in isolated guinea-pig papillary muscles.
Hayashi S; Kii Y; Tabo M; Fukuda H; Itoh T; Shimosato T; Amano H; Saito M; Morimoto H; Yamada K; Kanda A; Ishitsuka T; Yamazaki T; Kiuchi Y; Taniguchi S; Mori T; Shimizu S; Tsurubuchi Y; Yasuda S; Kitani S; Shimada C; Kobayashi K; Komeno M; Kasai C; Hombo T; Yamamoto K
J Pharmacol Sci; 2005; 99(5):423-37. PubMed ID: 16493184
[TBL] [Abstract][Full Text] [Related]
34. Early clinical development: evaluation of drug-induced torsades de pointes risk.
Vik T; Pollard C; Sager P
Pharmacol Ther; 2008 Aug; 119(2):210-4. PubMed ID: 18601950
[TBL] [Abstract][Full Text] [Related]
35. HERG-Lite: a novel comprehensive high-throughput screen for drug-induced hERG risk.
Wible BA; Hawryluk P; Ficker E; Kuryshev YA; Kirsch G; Brown AM
J Pharmacol Toxicol Methods; 2005; 52(1):136-45. PubMed ID: 15950494
[TBL] [Abstract][Full Text] [Related]
36. Early evaluation of compound QT prolongation effects: a predictive 384-well fluorescence polarization binding assay for measuring hERG blockade.
Deacon M; Singleton D; Szalkai N; Pasieczny R; Peacock C; Price D; Boyd J; Boyd H; Steidl-Nichols JV; Williams C
J Pharmacol Toxicol Methods; 2007; 55(3):238-47. PubMed ID: 17141530
[TBL] [Abstract][Full Text] [Related]
37. [Pre-clinical and clinical electrophysiological studies for the prediction of iatrogenic proarrhythmic effect (torsade de pointes)].
Jaillon P; Dupuis B; Dahan R
Therapie; 1997; 52(4):271-80. PubMed ID: 9437877
[TBL] [Abstract][Full Text] [Related]
38. Measuring the risk of torsades de pointes: electrocardiographic evaluation of PNU-142093 in conscious cynomolgus non-human primates using restraint and non-restraint procedures.
Bass AS; Hanson LA; Jackson TA
J Pharmacol Toxicol Methods; 2009; 60(1):51-7. PubMed ID: 19447184
[TBL] [Abstract][Full Text] [Related]
39. Selective block of IKs plays a significant role in MAP triangulation induced by IKr block in isolated rabbit heart.
Guérard NC; Traebert M; Suter W; Dumotier BM
J Pharmacol Toxicol Methods; 2008; 58(1):32-40. PubMed ID: 18582585
[TBL] [Abstract][Full Text] [Related]
40. [Insight into the mechanism of torsade de pointes (TDP) induced by cesium chloride].
Shen JB; Huang J; Jiang WP
Zhonghua Nei Ke Za Zhi; 1992 Jul; 31(7):407-9, 444. PubMed ID: 1338528
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
